A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait

Official record

Identifier

NCT07454850

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

Not provided in the official record

Lead sponsor

Novartis Pharmaceuticals

Target enrolment

400 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Mar 6, 2026

Last updated on the registry

Oct 1, 2026

Age

21 Years – 90 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion criteria

* Diagnosed with Ph+ve CML based on the European LeukemiaNet (ELN) and National Comprehensive Cancer Network (NCCN) diagnostic criteria.
* Received at least one line of TKI therapy.
* Having a documented pre-index period (equal to either 6 months prior to the index date or less in case of newly diagnosed patients).

Exclusion criteria

• Patients not fulfilling any of the above-mentioned inclusion criteria.

Indexed under

Leukemia